Genentech's Lucentis Heads to FDA

Genentech is touting the breadth and quality of data for the macular degeneration agent, including two Phase III trials and results showing superiority to Novartis/QLT's Visudyne.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet